Iowa Medicaid does not cover Wegovy or Zepbound for weight loss

Iowa Medicaid does not pay for drugs used for weight loss: state rules exclude them, and its preferred drug list marks Wegovy and Zepbound "Weight loss indication not covered." Wegovy (injection and tablets) and Zepbound are preferred drugs with prior authorization only for other approved uses: Wegovy to lower the risk of major cardiovascular events or for MASH, and Zepbound for obstructive sleep apnea. Saxenda and Foundayo are not on the preferred drug list.1237

Iowa Medicaid uses one prior authorization form (470-0058, revised October 2026) for GLP-1s prescribed for uses other than diabetes. It states that payment for weight loss will be denied and lists three covered uses.3456

• Cardiovascular risk reduction (Wegovy injection or tablets): adult 18 or older with established cardiovascular disease, a documented baseline BMI of 27 or more taken within 6 months of the request, and an evaluation for standard cardiovascular care.
• Obstructive sleep apnea (Zepbound): moderate to severe OSA, a baseline BMI of 30 or more, and an apnea/hypopnea index of 15 or more events per hour on a sleep study from the past three years; the patient must meet the FDA-approved age for OSA.
• MASH (Wegovy injection): noncirrhotic MASH with F2 to F3 liver fibrosis confirmed by elastography or biopsy, an evaluation for standard cardiometabolic care, and no significant alcohol use in the past year.
• All non-diabetes requests: use with a reduced-calorie diet and increased physical activity, no use with another GLP-1, and dosing within the FDA label; escalation doses are allowed for a set time and only listed maintenance doses are approved.
• Continuation: approved at an established maintenance dose; for OSA and MASH, documentation of a positive response to therapy is required.

Coverage for other uses the FDA has approved:

• Wegovy (injection), reduction of the risk of major adverse cardiovascular events in adults with established cardiovascular disease and a BMI of 27 or more (injection or tablets): Covered with prior authorization5
• Wegovy (injection), noncirrhotic MASH with F2 to F3 liver fibrosis (injection): Covered with prior authorization6
• Zepbound, moderate to severe obstructive sleep apnea with a BMI of 30 or more: Covered with prior authorization4

What changed, and when:

CMS BALANCE model: CMS's BALANCE model page names no participating states, and we found no Iowa Medicaid announcement that Iowa has joined.18

All State of Iowa employee health plans are provided by Wellmark Blue Cross and Blue Shield. The 2026 benefit booklets list weight reduction drugs among the drugs not covered under the prescription drug benefit.192021

Pharmacy benefit: Wellmark Blue Cross and Blue Shield (medical and BlueRx Value Plus prescription drug plan).

Marketplace (ACA) plans: Iowa's essential health benefits benchmark plan, a Wellmark CompleteBlue small-group plan, lists weight reduction drugs among the prescription drugs it does not cover.25

On the preferred drug list effective Oct. 1, 2026, Mounjaro, Ozempic, Rybelsus, Trulicity, Victoza and exenatide are preferred, and Bydureon BCise, Byetta and generic liraglutide are non-preferred. All diabetes GLP-1s need prior authorization: a type 2 diabetes request needs a current A1C, and a request for weight loss is denied.28

In 2025, Iowa Medicaid paid for 87,954 GLP-1 prescriptions, $87.1 million before rebates: 27 per 1,000 residents, against 32 across the states and DC, 21st of 51.73 It reimbursed 7 GLP-1 products that year. Every state, ranked.

CMS hides counts under 11 in a quarter, so 65 rows count as zero here and the totals are a floor.

Part D still excludes drugs used for weight loss alone: the Part D drug definition excludes drugs and uses Medicaid may exclude under SSA §1927(d)(2), which lists agents used for weight loss. Part D plans can cover GLP-1s for type 2 diabetes, MACE risk reduction (Wegovy), moderate-to-severe obstructive sleep apnea (Zepbound) and noncirrhotic MASH with fibrosis (Wegovy). For weight loss alone, the Medicare GLP-1 Bridge demonstration (July 1, 2026 – Dec 31, 2027) gives eligible Part D enrollees Foundayo, Wegovy or Zepbound KwikPen for a $50 monthly copay, outside the Part D benefit. The BALANCE Model's Part D component is not launching in 2027.4849394035432838

• Medicare GLP-1 Bridge (demonstration) (active, from 2026-07-01): Runs July 1, 2026 to December 31, 2027 (extended). Outside the Part D benefit: $50 copay per one-month supply (28 or 30 days), Part D deductible does not apply, the copay does not count toward TrOOP, no low-income subsidy. Covers Foundayo, Wegovy (injection or tablet) and Zepbound KwikPen only (not Zepbound single-dose vials or pens). Eligibility: age 18+ and, when starting GLP-1 therapy, BMI ≥35; or BMI ≥30 with heart failure with preserved ejection fraction, uncontrolled hypertension, or CKD stage 3a+; or BMI ≥27 with prediabetes, prior heart attack or stroke, or symptomatic peripheral artery disease. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible (their Part D plan may cover GLP-1s for those conditions). Prior authorization required; valid through Dec 31, 2027 unless the patient changes GLP-1s.3536372843444546474241
• BALANCE Model — Medicare Part D component (not launching in 2027; future implementation described by CMS only as 'potential'): Originally announced to launch in Part D in January 2027. CMS's BALANCE page FAQ now refers to 'the BALANCE Model not launching in Medicare in 2027' and extends the Bridge through Dec 31, 2027 to collect data 'ahead of potential implementation of BALANCE in Part D'. No new start date is published.303228

In 2024, Medicare Part D drug plans paid for 231,196 GLP-1 claims from prescribers in Iowa, $268.5 million in total drug cost.74

The lowest price among the programs that ship to every state is WellMedr: $492 for 12 months ($41 a month); $99 month to month, fees in.78 Includes a sale seen on November 5, 2026; the price returns to the standing price when it ends. The cheapest programs, ranked, or every program, ranked on our score.

Prices are what each program charged at its own checkout, fees in, with the total due for the plan length first. Compounded GLP-1s are prepared by a pharmacy to a prescription, and they are not FDA-approved; the section on compounding explains what that means.

We may earn a commission when you sign up through some links. It never changes our order or scores. How we make money

29 more programs we rank ship to fewer than 50 states, or don’t say how many. We don’t record which states they leave out, so check Iowa on their sites: Embody, Collective, SnagRx, Enhanced, Direct Meds, Gala Health, GobyMeds, CoreAge Rx, Maximus Tribe, Brightmeds, SkinnyRx, Willow, Strut Health, Enhance MD, LumiMeds, VivioMD, MEDGm, MyDrHank, Zevay, LevelsRx, Hume Care, ReadyRx, Hers, Luvo Health, Remedy Meds, Hims, DudeMeds, G-Plans and Found.

The makers also sell some brand-name GLP-1s for cash, at the same price in every state, with a prescription:

These are standing prices. The Zepbound and Wegovy rankings list each dose and the terms of each offer.

Compounded GLP-1s are prepared by a pharmacy to a prescription. They are not FDA-approved: the FDA doesn’t review their safety, effectiveness or quality before they’re sold, and they are not the same as Wegovy or Zepbound. Formulas can differ from one pharmacy to the next, and some add ingredients such as vitamin B12.7980 Compounding pharmacies are licensed and inspected by state boards of pharmacy; outsourcing facilities (503B) also register with the FDA and are inspected by it. The FDA can issue warning letters when either breaks rules on safety or sterility.

We found no action on compounded GLP-1s by Iowa’s board of pharmacy or attorney general on their own sites.26

The FDA’s register lists 0 outsourcing facilities (503B) in Iowa, as of November 6, 2026.75